arrow
D

Dok Hyun Yoon

university of ulsan
H指数:44
被引数:7,361

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Patient-Reported Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab plus Gemcitabine and Oxaliplatin in STARGLO

在STARGLO研究中,接受Glofitamab联合吉西他滨和奥沙利铂治疗复发或难治性弥漫性大B细胞淋巴瘤患者的患者报告结局

2026-10-110
OAAI
Danburstotug, an anti-PD-L1 antibody, in relapsed/refractory extra-nodal natural killer/T-cell lymphoma: The phase 2 DISTINKT study

丹努斯妥昔单抗(Danburstotug),一种抗PD-L1抗体,在复发/难治性结外自然杀伤/T细胞淋巴瘤中的应用:DISTINKT二期研究

2026-09-050
PRE
Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry

套细胞淋巴瘤巩固治疗的治疗演变及对生存的影响:来自亚太地区真实世界登记研究的见解

2026-05-290
OAAI
A novel prognostic model for primary central nervous system lymphoma incorporating clinico-laboratory parameters

一种整合临床与实验室参数的原发性中枢神经系统淋巴瘤新型预后模型

2025-12-030
PRE
Prognostic significance of pretransplant 18F-FDG PET/CT metrics in relapsed/refractory diffuse large B-cell lymphoma with partial response to salvage chemotherapy prior to autologous stem cell transplantation

自体干细胞移植前对挽救性化疗部分缓解的复发/难治性弥漫大B细胞淋巴瘤中,移植前18F-FDG PET/CT指标的预后意义

2025-10-010
OAAI
Real-World Efficacy and Safety of Teclistamab for Patients with Released or Refractory Multiple Myeloma: Korean, Nationwide, Retrospective Analysis of an Named Patient Program

托西卡玛单抗在复发或难治性多发性骨髓瘤患者中的真实世界疗效与安全性:韩国全国性回顾性分析(基于指定患者用药计划)

BLOOD
IF23.1
2024-11-050
PRE
Retrospective Analysis of Treatment Outcome Differences with and without Autologous Stem Cell Transplantation in Patients with Dialysis-Dependent Multiple Myeloma (DDMM): KMM2304 Study

回顾性分析自体干细胞移植与未进行自体干细胞移植的透析依赖性多发性骨髓瘤(DDMM)患者治疗结局差异:KMM2304研究

BLOOD
IF23.1
2024-11-050
PRE
Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

卡非佐米或伊沙佐米为基础治疗方案治疗的多发性骨髓瘤患者的预后影响:反应动力学及影响因素

BLOOD
IF23.1
2024-11-050
PRE
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 study
2024-06-061
OAAI
Long-term efficacy and safety of tucidinostat inpatients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results
2024-06-060
OAAI
Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab

daratumumab治疗的结外自然杀伤/T细胞淋巴瘤患者的免疫分析

2024-01-182
OAAI